drugset
drugset / Trial / NCT02295865

A Study to Evaluate Safety and Efficacy of Toreforant (JNJ-38518168) in Participants With Moderate to Severe Plaque-type Psoriasis

NCT02295865 ↗

Phase 2 Completed 62 enrolled Janssen Research & Development, LLC
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to evaluate the efficacy, safety and tolerability of JNJ-38518168 in participants with moderate to severe plaque-type psoriasis (common genetically determined, chronic, inflammatory skin disease characterized by rounded erythematous, dry, scaling patches).

Timeline

Start
2014-11-17
Primary completion
2016-03-11
Completion
2016-03-11

Drugs

EvaluationDrugModalityDoseRoute
Subject TOREFORANT Small molecule 3 mg Oral
Subject TOREFORANT Small molecule 30 mg Oral
Subject TOREFORANT Small molecule 60 mg Oral

Indications

psoriasis